motixafortide
motixafortide: 5 clinical trials tracked.
motixafortide evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about motixafortide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)
Primary endpoint: Incidence and severity of systemic reactions
Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motixafortide
Primary endpoint: To assess the safety and tolerability of motixafortide in participants with sickle cell disease (SCD) as determined by the incidence of adverse events.
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Primary endpoint: Absolute number and relative proportions of CD34+ cell subsets by extended immunophenotypic profiling using multicolor fluorescence activated cell sorting (mFACS) on the apheresis product
A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Primary endpoint: Safety and tolerability as assessed by the incidence of dose-limiting toxicities (DLTs)
A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma
Primary endpoint: Overall Response Rate (Complete Response (CR) + Partial Response (PR))